Comparative Benefits and Harms of Antidepressant, Psychological, Complementary, and Exercise Treatments for Major Depression: An Evidence Report for a Clinical Practice Guideline From the American College of Physicians
The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Primary care patients and clinicians may prefer options other than second-generation antidepressants for the treatment of major depressive disorder (MDD). The comparative benefits and harms of antidepressants and alternative treatments are unclear. PURPOSE: To compare the benefits and harms of second-generation antidepressants and psychological, complementary and alternative medicine (CAM), and exercise treatments as first- and second-step interventions for adults with acute MDD. DATA SOURCES: English-, German-, and Italian-language studies from multiple electronic databases (January 1990 to September 2015); trial registries and gray-literature databases were used to identify unpublished research. STUDY SELECTION: Two investigators independently selected comparative randomized trials of at least 6 weeks' duration on health outcomes of adult outpatients; nonrandomized studies were eligible for harms. DATA EXTRACTION: Reviewers abstracted data on study design, participants, interventions, and outcomes; rated the risk of bias; and graded the strength of evidence. A senior reviewer confirmed data and ratings. DATA SYNTHESIS: 45 trials met inclusion criteria. On the basis of moderate-strength evidence, cognitive behavioral therapy (CBT) and antidepressants led to similar response rates (relative risk [RR], 0.90 [95% CI, 0.76 to 1.07]) and remission rates (RR, 0.98 [CI, 0.73 to 1.32]). In trials, antidepressants had higher risks for adverse events than most other treatment options; no information from nonrandomized studies was available. The evidence was too limited to make firm conclusions about differences in the benefits and harms of antidepressants compared with other treatment options as first-step therapies for acute MDD. For second-step therapies, different switching and augmentation strategies provided similar symptom relief. LIMITATION: High dropout rates, dosing inequalities, small sample sizes, and poor assessment of adverse events limit confidence in the evidence. CONCLUSION: Given their similar efficacy, CBT and antidepressants are both viable choices for initial treatment of MDD. PRIMARY FUNDING SOURCE: Agency for Healthcare Research and Quality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kessler, R. C., Berglund, P., Demler, O., Jin, R., Koretz, D., Merikangas, K. R., Rush, A. J., Walters, E. E., & Wang, P. S. (2003) · JAMA · doi:10.1001/jama.289.23.3095 · Cited by 7,988
Cooney, G. M., Dwan, K., Greig, C. A., Lawlor, D. A., Rimer, J., Waugh, F. R., McMurdo, M., & Mead, G. E. (2013) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd004366.pub6 · Cited by 1,834
Dimidjian, S., Hollon, S. D., Dobson, K. S., Schmaling, K. B., Kohlenberg, R. J., Addis, M. E., Gallop, R., McGlinchey, J. B., Markley, D. K., Gollan, J. K., et al. (2006) · Journal of Consulting and Clinical Psychology · doi:10.1037/0022-006x.74.4.658 · Cited by 1,607 · cited 7×
“32]) in a meta-analysis of 3 trials (432 patients) after 12 to 16 weeks of follow-up (40, 41, 44, 47).”
InfluentialEffects of exercise training on older patients with major depression
Blumenthal, J. A., Babyak, M. A., Moore, K. A., Craighead, W. E., Herman, S., Khatri, P., Waugh, R., Napolitano, M. A., Forman, L. M., Appelbaum, M., et al. (1999) · Archives of Internal Medicine · doi:10.1001/archinte.159.19.2349 · Cited by 1,277 · cited 2×
“66%) between treatment groups (71); the other found statistically significantly lower remission rates in elderly patients (aged ≥65 years) receiving sertraline monotherapy than those assigned to a combination of sertraline and aerobic exercise (45% vs.”
Severity classification on the Hamilton depression rating scale
Zimmerman, M., Martinez, J. H., Young, D., Chelminski, I., & Dalrymple, K. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2013.04.028 · Cited by 1,199 · cited 1×
“We classified patients' severity of depression by using the categorization systems of the University of Pittsburgh Epidemiology Data Center (13) and Zimmerman and colleagues (14).”
Exercise Treatment for Major Depression: Maintenance of Therapeutic Benefit at 10 Months
Babyak, M., Blumenthal, J. A., Herman, S., Khatri, P., Doraiswamy, M., Moore, K., Edward Craighead, W., Baldewicz, T. T., & Ranga Krishnan, K. (2000) · Psychosomatic Medicine · doi:10.1097/00006842-200009000-00006 · Cited by 1,063
Bupropion-SR, Sertraline, or Venlafaxine-XR after Failure of SSRIs for Depression
Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Stewart, J. W., Nierenberg, A. A., Thase, M. E., Ritz, L., Biggs, M. M., Warden, D., Luther, J. F., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052963 · Cited by 1,033
Exercise and Pharmacotherapy in the Treatment of Major Depressive Disorder
Blumenthal, J. A., Babyak, M. A., Doraiswamy, P. M., Watkins, L., Hoffman, B. M., Barbour, K. A., Herman, S., Craighead, W. E., Brosse, A. L., Waugh, R., et al. (2007) · Psychosomatic Medicine · doi:10.1097/psy.0b013e318148c19a · Cited by 1,019
Medication Augmentation after the Failure of SSRIs for Depression
Trivedi, M. H., Fava, M., Wisniewski, S. R., Thase, M. E., Quitkin, F., Warden, D., Ritz, L., Nierenberg, A. A., Lebowitz, B. D., Biggs, M. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa052964 · Cited by 1,002
Cognitive Therapy vs Medications in the Treatment of Moderate to Severe Depression
DeRubeis, R. J., Hollon, S. D., Amsterdam, J. D., Shelton, R. C., Young, P. R., Salomon, R. M., O’Reardon, J. P., Lovett, M. L., Gladis, M. M., Brown, L. L., et al. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.4.409 · Cited by 989 · cited 4×
“Of the 20 included trials on psychological interventions, 11 assessed various CBTs (24, 26, 27, 32, 33, 37, 39, 40, 43, 44, 47, 50).”
Influential
Research works printed but not linked: 51
- Rimer J, 2012, Cochrane Database Syst Rev, 7, CD004366
- Maratos AS, 2008, Cochrane Database Syst Rev, CD004517
- Jorm AF, 2008, Cochrane Database Syst Rev, CD007142
- Smith CA, 2010, Cochrane Database Syst Rev, CD004046
- Cooney GM, 2013, Cochrane Database Syst Rev, 9, CD004366
- De Berardis D, 2015, CNS Neurol Disord Drug Targets
- 10.1136/bmj.d5928 · DOI · Paper page
- 10.1016/S0149-2918(00)89010-4 · DOI · Paper page
- 10.1097/01.jcp.0000178416.60426.29 · DOI · Paper page
- 10.1017/S0033291710000553 · DOI · Paper page
- 10.1017/S1461145709000224 · DOI · Paper page
- 10.1080/00048670701827275 · DOI · Paper page
- 10.4088/JCP.13m08591 · DOI · Paper page
- 10.1590/S1516-44462006000100007 · DOI · Paper page
- 10.1176/ps.2009.60.3.337 · DOI · Paper page
- Shamsaei F, 2008, Hong Kong Journal of Psychiatry, 18, 76
- 10.1016/j.jad.2006.07.012 · DOI
- 10.1089/acm.2011.0637 · DOI · Paper page
- 10.1001/jama.290.1.57 · DOI · Paper page
- 10.1016/j.jad.2013.08.036 · DOI
- 10.1136/bmj.320.7226.26 · DOI · Paper page
- 10.1159/000151388 · DOI · Paper page
- 10.1192/bjp.bp.112.122663 · DOI · Paper page
- 10.1002/jclp.20487 · DOI · Paper page
- 10.1016/j.jad.2007.10.015 · DOI
- 10.1159/000104705 · DOI · Paper page
- 10.1002/jclp.20550 · DOI · Paper page
- 10.1002/da.20758 · DOI · Paper page
- 10.1002/da.20585 · DOI
- 10.4103/1673-5374.125353 · DOI
- Huang Y, 2005, International Journal of Clinical Acupuncture, 14, 7
- 10.1016/j.jpsychires.2013.02.004 · DOI
- 10.1089/acm.2008.0607 · DOI · Paper page
- 10.1007/BF02850017 · DOI
- 10.1007/s00406-004-0532-z · DOI
- 10.1001/jama.287.14.1807 · DOI · Paper page
- 10.1055/s-2005-837807 · DOI · Paper page
- 10.1055/s-2006-931544 · DOI · Paper page
- Harrer G, 1999, Arzneimittelforschung, 49, 289
- 10.1159/000115779 · DOI
- 10.1097/00004850-200015020-00001 · DOI · Paper page
- 10.1136/bmj.38356.655266.82 · DOI · Paper page
- van Gurp G, 2002, Can Fam Physician, 48, 905
- 10.1136/bmj.h4320 · DOI · Paper page
- 10.1249/MSS.0b013e31816b877c · DOI · Paper page
- 10.1192/bjp.bp.114.150516 · DOI · Paper page
- 10.1097/YIC.0b013e3282f424c2 · DOI · Paper page
- 10.1016/j.jad.2009.07.005 · DOI · Paper page
- 10.1097/NMD.0b013e31820caefb · DOI · Paper page
- Linde K, 2008, Cochrane Database Syst Rev, CD000448
- 10.1016/j.euroneuro.2008.08.009 · DOI · Paper page
Cited by
Anxiety, depression, and the microbiome: A role for gut peptides
Lach, G., Schellekens, H., Dinan, T. G., & Cryan, J. F. (2018) · Neurotherapeutics · doi:10.1007/s13311-017-0585-0 · Cited by 573
McCarron, R. M., Shapiro, B., Rawles, J., & Luo, J. (2021) · Annals of Internal Medicine · doi:10.7326/aitc202105180 · Cited by 492
Psychological Treatment of Depression in Primary Care: Recent Developments
Cuijpers, P., Quero, S., Dowrick, C., & Arroll, B. (2019) · Current Psychiatry Reports · doi:10.1007/s11920-019-1117-x · Cited by 296
Qaseem, A., Barry, M. J., Kansagara, D., & for the Clinical Guidelines Committee of the American College of Physicians (2016) · Annals of Internal Medicine · doi:10.7326/m15-2570 · Cited by 279
“org) and the accompanying systematic review (9) for additional details of the evidence.”
BackgroundMethodInfluentialACOG Committee on Clinical Practice Guidelines–Obstetrics (2023) · Obstetrics & Gynecology · doi:10.1097/aog.0000000000005202 · Cited by 252
Association of Antidepressant Use With Adverse Health Outcomes: A Systematic Umbrella Review
Dragioti, E., Solmi, M., Favaro, A., Fusar-Poli, P., Dazzan, P., Thompson, T., Stubbs, B., Firth, J., Fornaro, M., Tsartsalis, D., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.2859 · Cited by 215
Gartlehner, G., Wagner, G., Matyas, N., Titscher, V., Greimel, J., Lux, L., Gaynes, B. N., Viswanathan, M., Patel, S., & Lohr, K. N. (2017) · BMJ Open · doi:10.1136/bmjopen-2016-014912 · Cited by 192
Self-citationKandola, A., Hendrikse, J., Lucassen, P. J., & Yücel, M. (2016) · Frontiers in Human Neuroscience · doi:10.3389/fnhum.2016.00373 · Cited by 155
“Pharmacological treatments are generally associated with a higher risk of inducing adverse side effects than non-pharmacological interventions in patients of MDD or schizophrenia (Gartlehner et al., 2015, 2016).”
Recchia, F., Leung, C. K., Chin, E. C., Fong, D. Y., Montero, D., Cheng, C. P., Yau, S. Y., & Siu, P. M. (2022) · British Journal of Sports Medicine · doi:10.1136/bjsports-2022-105964 · Cited by 117
“Gartlehner et al 34 compared pharmacological versus non-pharmacological treatments, but only direct evidence was analysed.”
BackgroundComplementary Therapies for Mental Health Disorders
Asher, G. N., Gerkin, J., & Gaynes, B. N. (2017) · Medical Clinics of North America · doi:10.1016/j.mcna.2017.04.004 · Cited by 93
Self-citationNeuropharmacological classification of antidepressant agents based on their mechanisms of action
Fasipe, O. (2018) · Archives of Medicine and Health Sciences · doi:10.4103/amhs.amhs_7_18 · Cited by 80
“These classes of antidepressants appear to enhance the synaptic availability of 5‐HT, norepinephrine, and/or dopamine.[2,3,7,8]”
BackgroundAbdollahi, A., LeBouthillier, D. M., Najafi, M., Asmundson, G. J. G., Hosseinian, S., Shahidi, S., Carlbring, P., Kalhori, A., Sadeghi, H., & Jalili, M. (2017) · Journal of Affective Disorders · doi:10.1016/j.jad.2017.05.012 · Cited by 62
Metadata
- Authors
- Gartlehner, G., Gaynes, B. N., Amick, H. R., Asher, G. N., Morgan, L. C., Coker-Schwimmer, E., Forneris, C., Boland, E., Lux, L. J., Gaylord, S., Bann, C., Pierl, C. B., & Lohr, K. N.
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2016-03-01
- Volume
- 164
- Issue
- 5
- Pages
- 331-341
- ISSN
- 0003-4819 (ISSN-L)
- 1539-3704
- OpenAlex
- W2291849082
- Cited by
- 132
- References
- 29
- FWCI
- 13.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.acpjournals.org/journal/aim/text-and-data-mining (tdm)
- Funders
- Agency for Healthcare Research and Quality (290-2012-00008i)
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.